Business Standard

Tuesday, January 21, 2025 | 08:16 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Cancer Drugs

Biocon urges govt to exempt cancer, rare-disease drugs from tax in Budget

To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties for high-tech instruments

Biocon urges govt to exempt cancer, rare-disease drugs from tax in Budget
Updated On : 20 Jan 2025 | 9:27 AM IST

Health cover against cancer: Check policy for exclusions, sub-limits

Cancer-specific policies, which only cover cancer, are available as indemnity-based or fixed-benefit plans

Health cover against cancer: Check policy for exclusions, sub-limits
Updated On : 14 Jan 2025 | 11:02 PM IST

Eli Lilly to buy cancer drugmaker Scorpion Therapeutics for up to $2.5 bn

Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors

Eli Lilly to buy cancer drugmaker Scorpion Therapeutics for up to $2.5 bn
Updated On : 13 Jan 2025 | 8:21 PM IST

Mankind Pharma inks pact with Innovent for immunotherapy drug in India

Drug used to treat non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin's lymphoma will be priced competitively

Mankind Pharma inks pact with Innovent for immunotherapy drug in India
Updated On : 28 Dec 2024 | 10:20 AM IST

What is 'face age'? Can this novel AI-tool help fight diseases like cancer?

AI-powered 'face age' tests are helping doctors predict patient outcomes, even tailor cancer treatments and has the potential to revolutionise healthcare

What is 'face age'? Can this novel AI-tool help fight diseases like cancer?
Updated On : 27 Dec 2024 | 2:01 PM IST

Aiims in process of making low cost therapy for treating multiple myeloma

Doctors at AIIMS, Delhi are in the process of developing a low cost antibody-based adaptive cellular therapy for treatment of multiple myeloma, a form of blood cancer. This kind of therapy is expected to make advanced treatments like CAR-T cell therapies more affordable and accessible for patients in India. The Chimeric antigen receptor (CAR) T-cell therapy is a form of adaptive cellular therapy in which a patient's T cells are isolated, genetically modified and infused back in the patients body to recognise and kill the cancer cells, said Dr Mayank Singh, Additional Professor in the Department of Medical Oncology at Dr B R Ambedkar Institute Rotary Cancer Hospital, (BRAIRCH), AIIMS here. It is based on targeting B-cell maturation antigen (BCMA) which helps to target specific tumour antigens which are found cancer cells specially in cases multiple myeloma. "So the therapy developed by the AIIMS researchers recognises BCMA as a target on multiple myeloma cells to eliminate them," Si

Aiims in process of making low cost therapy for treating multiple myeloma
Updated On : 21 Dec 2024 | 6:57 PM IST

US drug body approves Merus' therapy for lung, pancreatic cancer patients

The therapy, branded as Bizengri, targets the NRG1 gene, which is associated with formation and progression of several tumors

US drug body approves Merus' therapy for lung, pancreatic cancer patients
Updated On : 05 Dec 2024 | 8:55 AM IST

Navjot Singh Sidhu, wife get Rs 850 crore notice over cancer cure claims

Chhattisgarh Civil Society (CCS) issued the notice to Navjot Kaur and her husband, Navjot Singh Sidhu for the claim that cancer can be cured with a diet containing lemonade, raw turmeric, and neem

Navjot Singh Sidhu, wife get Rs 850 crore notice over cancer cure claims
Updated On : 29 Nov 2024 | 1:19 PM IST

Dr Reddy's launches Toripalimab to treat nasopharyngeal cancer in India

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab

Dr Reddy's launches Toripalimab to treat nasopharyngeal cancer in India
Updated On : 28 Nov 2024 | 1:46 PM IST

AstraZeneca Pharma gets nod for sale, distribution of cancer drug Lynparza

The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults

AstraZeneca Pharma gets nod for sale, distribution of cancer drug Lynparza
Updated On : 26 Nov 2024 | 3:36 PM IST

Docs dismiss Sidhu's claim on cancer diet; call it unscientific, baseless

Doctors, including the director of Tata Memorial Hospital, have refuted Sidhu's claim that his wife overcame cancer following a strict diet

Docs dismiss Sidhu's claim on cancer diet; call it unscientific, baseless
Updated On : 25 Nov 2024 | 2:53 PM IST

NPPA asks pharma manufacturers to cut price of 3 anti-cancer drugs

The government has asked the companies to reduce prices of three anti-cancer drugs to pass on the benefit of customs duty exemption and GST reduction to the consumers. In line with the government's commitment to ensure the availability of drugs at affordable prices, the National Pharmaceutical Pricing Authority (NPPA) has issued an office memorandum directing the concerned manufacturers to reduce the MRP on three anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab. This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty, the Ministry of Chemicals and Fertilisers said in a statement. The Department of Revenue, Ministry of Finance, issued a notification dated July 23, this year reducing the customs duty to nil on the three drugs. "Accordingly, there should be a reduction in MRP of these drugs in the market and benefits of reduced taxes and duties should be passed on to the consumers,"

NPPA asks pharma manufacturers to cut price of 3 anti-cancer drugs
Updated On : 29 Oct 2024 | 4:52 PM IST

Immunotherapy was meant to defeat cancer but what happened to great promise

This works because cancers have fooled the body by using its own natural safety switches, or checkpoints

Immunotherapy was meant to defeat cancer but what happened to great promise
Updated On : 24 Oct 2024 | 10:28 AM IST

Disparities between rich, poor nations in cancer drugs availability: Study

New cancer drugs launched each year increased from 0.5 in the 1990s to over eight in 2022 among high-income countries, whereas they increased from 0.1 to 1.5 a year among upper-middle-income countries, according to a global analysis revealing "significant" and "widening" disparities. New drug launches remained minimal in lower-middle-income and low-income countries, it found. Published in the British Medical Journal (BMJ) Global Health, the analysis highlighted significant disparities in both availability and timeliness of these medicines worldwide, according to researchers. The inequities could explain the poor cancer outcomes across many countries, especially the low- and middle-income ones, where mortality-to-incidence ratios have been studied to be higher, despite overall cases being lower, the researchers, including those from The Pennsylvania State University, US, said. The measure 'mortality-to-incidence ratio' is used to compare inequities in cancer outcomes. It is calculat

Disparities between rich, poor nations in cancer drugs availability: Study
Updated On : 09 Oct 2024 | 4:57 PM IST

Zydus Lifesciences receives USFDA approval to produce prostrate cancer drug

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate cancer treatment drug. The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing. Enzalutamide tablets are androgen receptor inhibitors indicated for the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. The product would be manufactured at the Group's manufacturing site at SEZ, Ahmedabad. As per IQVIA MAT July 2024 data, Enzalutamide tablets (40 mg and 80 mg) had annual sales of USD 1,417.2 million in the US. The Zydus group now has 400 approvals and has so far filed over 465 Abbreviated New Drug Application (ANDAs) since the commencement of the filing process in FY 2003-04, it said.

Zydus Lifesciences receives USFDA approval to produce prostrate cancer drug
Updated On : 02 Oct 2024 | 10:58 PM IST

Sun Pharma signs licensing pact with Philogen for cancer medication

Sun Pharmaceutical Industries on Tuesday said it has inked a global licensing pact with Italian-Swiss firm Philogen for an anti-cancer drug. As per the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun, a speciality product of Philogen. Fibromun, an innovative anti-cancer immunotherapy, is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma. As per the pact, Philogen will complete the ongoing pivotal clinical trials for the product, pursue marketing authorisation with regulatory authorities, and manufacture commercial supplies, the Mumbai-based drug major said in a statement. Sun Pharma will be responsible for commercialisation activities, it added. The two partner companies will share post-commercialisation economics in about 45(Philogen):55(Sun Pharma) ratio, Sun Pharma said. The company did not disclose other financial terms. "Fibromun's progress through development has been qui

Sun Pharma signs licensing pact with Philogen for cancer medication
Updated On : 01 Oct 2024 | 11:57 AM IST

AstraZeneca's experimental drug disappoints in breast cancer survival trial

The overall survival, or OS rates, in the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd), did not achieve statistical significance

AstraZeneca's experimental drug disappoints in breast cancer survival trial
Updated On : 23 Sep 2024 | 1:10 PM IST

Quad leaders to unveil milestone initiative to combat cancer during summit

Top Quad leaders will unveil a "milestone" initiative on Saturday to prevent, detect, treat and alleviate the impact of cancer on patients and their families, when they gather in Wilmington in the US for their annual summit. Being hosted by US President Joe Biden, the "Quad Leaders Summit" will be attended by Prime Minister Narendra Modi, his Australian counterpart Anthony Albanese and Japan's Fumio Kishida. The leaders are expected to deliberate on pressing global challenges, including the Russia-Ukraine conflict, escalating tensions in West Asia and the overall situation in the Indo-Pacific. At a media briefing on Modi's visit to the United States from September 21-23, Foreign Secretary Vikram Misri said the "signature" "Cancer Moonshot" event will take place on the sidelines of the Quad summit in Wilmington, Delaware. "One of the signature initiatives to be unveiled on the sidelines is the Cancer Moonshot event," he said. "Through this milestone initiative, the Quad aims to ...

Quad leaders to unveil milestone initiative to combat cancer during summit
Updated On : 19 Sep 2024 | 9:34 PM IST

Japanese firm Daiichi wants to go alone in search of targeted cancer drugs

AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and was the top-selling ADC globally in 2023

Japanese firm Daiichi wants to go alone in search of targeted cancer drugs
Updated On : 17 Sep 2024 | 9:29 AM IST

ICMR to advance 1st in-human trials for Zika, flu, blood cancer therapies

First-in-human trial is a type of clinical trial in which a new drug, procedure or treatment is tested in humans for the first time

ICMR to advance 1st in-human trials for Zika, flu, blood cancer therapies
Updated On : 14 Sep 2024 | 4:06 PM IST